Polycystic ovary syndrome (PCOS) affects an estimated 10% of women of reproductive age and is the most common cause of anovulatory infertility. The conventional understanding frames it as a reproductive hormone disorder — elevated androgens, irregular periods, polycystic ovaries on ultrasound. The m

PCOS Is a Metabolic Condition, Not Just a Hormone Disorder

Polycystic ovary syndrome (PCOS) affects an estimated 10% of women of reproductive age and is the most common cause of anovulatory infertility. The conventional understanding frames it as a reproductive hormone disorder — elevated androgens, irregular periods, polycystic ovaries on ultrasound. The more contemporary understanding, supported by two decades of research, is that PCOS is fundamentally a metabolic condition with reproductive consequences. The androgens are a downstream effect of insulin resistance, hyperinsulinaemia, and the metabolic dysregulation that characterises the condition.

The Insulin-Androgen Connection

Hyperinsulinaemia drives androgen production in theca cells of the ovary through two mechanisms. First, insulin stimulates LH (luteinising hormone) secretion from the pituitary, increasing the stimulus for androgen production in the ovary. Second, insulin inhibits the hepatic production of sex hormone-binding globulin (SHBG), the protein that carries androgens in blood. With less SHBG, more free androgens are available to exert effects on hair follicles, skin, and the hypothalamus. This means that for a given testosterone level, the free androgen index is higher in insulin-resistant women with PCOS than in women with normal insulin sensitivity.

The practical implication is that the most effective treatments for PCOS are metabolic rather than hormonal. Inositols — specifically myo-inositol and D-chiro-inositol — improve insulin sensitivity, reduce hyperinsulinaemia, and as a downstream effect reduce androgen levels, restore ovulatory function, and improve fertility outcomes. Berberine, the botanical compound with demonstrated insulin-sensitising activity, has shown comparable effects to metformin in PCOS patients with the advantage of better tolerability and additional lipid-improving effects.

PCOS and the Gut Microbiome

The gut microbiome in PCOS patients shows characteristic differences from healthy controls — reduced diversity, altered Firmicutes-to-Bacteroidetes ratios, and decreased bacterial production of short-chain fatty acids. This dysbiosis is thought to contribute to the metabolic dysfunction of PCOS through multiple mechanisms: increased intestinal permeability leading to endotoxin translocation, altered bile acid metabolism, and reduced SCFA production. Probiotic and prebiotic interventions have shown preliminary evidence for improving both metabolic and reproductive outcomes in PCOS.

What You Can Do Today

If you have PCOS diagnosed or strongly suspected, the metabolic approach is the evidence-based first-line treatment. Inositols at 2-4g daily (myo-inositol preferred over D-chiro for most patients) improve insulin sensitivity, reduce androgens, and restore ovulatory function within 3-6 months in most women. Berberine at 1000-1500mg daily is an effective alternative for those who do not tolerate inositols. Dietary strategies — low-glycaemic-load diets, adequate protein, Mediterranean-pattern eating — support the metabolic approach alongside supplementation.